Treatment of Chronic Urticaria with Traditional Chinese Medicine by Regulating PI3K/Akt Molecular Pathway： A Review
10.13422/j.cnki.syfjx.20240618
- VernacularTitle:中医药调控PI3K/Akt分子通路治疗慢性荨麻疹研究进展
- Author:
Kaifeng JI
1
;
Haibin CAI
1
;
Zhouwei WU
1
;
Yuting ZHENG
1
;
Xiaoqian XU
1
;
Yu SONG
1
Author Information
1. Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine ， Shanghai 200032， China
- Publication Type:Journal Article
- Keywords:
chronic urticaria;
traditional Chinese medicine;
phosphatidylinositol kinase/serine-threonine protein kinase B signaling pathway;
network pharmacology;
review
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(17):292-298
- CountryChina
- Language:Chinese
-
Abstract:
Chronic urticaria （CU） is a common skin disease worldwide， and its incidence is increasing year by year in various regions. Clinical manifestations such as severe itching can affect normal work， sleep， and daily life and increase the negative psychological burden caused by stress， anxiety， and depression. Mast cell activation and degranulation induced by immunoglobulin（Ig）E hypersensitivity is one of the core pathogenic mechanisms of CU， and there is no cure. Antihistamines such as cetirizine and loratadine are preferred for the clinical treatment of CU. Although they can effectively improve clinical manifestations such as itchiness， long-term application can increase the risk of adverse reactions and drug resistance. The phosphatidylinositol kinase/serine-threonine protein kinase B（PI3K/Akt） signaling pathway， as a classical signaling pathway regulated by phosphatidylinositol and tyrosine kinase receptor （RTK）， is a key target regulating the production and release of cytokines in macrophages and affecting the migration of leukocytes and the activation of mast cells and inflammation， and it can be involved in a variety of metabolic processes， such as mast cell activation and degranulation induced by IgE hypersensitivity and abnormal activation of the complement system so that the PI3K/Akt molecular pathway could be an important target for the future eradication of CU. However， the mechanism and potential role of the PI3K/Akt signaling pathway in the treatment of CU are less reported in China. Now， this paper reviewed the molecular mechanism of PI3K/Akt signaling pathway regulation in the treatment of CU and provided corroborative evidence and therapeutic strategy choices for the treatment of CU with traditional Chinese medicine （TCM） from the perspectives of molecular regulation and network pharmacology analysis.
